基于骨髓样本的多发性骨髓瘤微小残留病检测中国专家共识（2024）
[Chinese expert consensus on minimal residual disease detection in multiple myeloma based on bone marrow samples (2024)].
发表日期：2024 Jun 14
作者：
,
来源：
Experimental Hematology & Oncology
摘要：
多发性骨髓瘤（MM）是第二常见的血液系统恶性肿瘤。标准的整体治疗模式和新的药物治疗方案大大提高了MM患者的生存率；然而，微小残留病（MRD）会导致大多数患者复发。因此，有必要在传统血清学疗效评估的基础上结合MRD检测，以实现对患者疾病状态的更准确评估。目前，新一代流式细胞术（NGF）和新一代测序（NGS）是基于骨髓样本检测MRD的主流技术。为规范和规范MRD检测，专家组讨论制定了NGF和NGS技术在MM患者骨髓MRD检测中应用的中国专家共识。
Multiple myeloma (MM) is the second most common hematologic malignant tumor. Standard holistic treatment model and new drug-based regimens have greatly improved the survival of patients with MM; however, minimal residual disease (MRD) causes relapse in most patients. Therefore, combining MRD testing on the basis of traditional serological efficacy evaluation is necessary to achieve a more accurate assessment of the patient's disease status. At present, next-generation flow cytometry (NGF) and next-generation sequencing (NGS) are the mainstream technologies for detecting MRD based on bone marrow samples. To standardize and normalize MRD detection, the expert group discussed and formulated Chinese expert consensus on the application of NGF and NGS technology for bone marrow MRD detection in patients with MM.